Loading...
The FDA Changed Everything
On May 23, 2017, the FDA approved the first cancer treatment (pembrolizumab) for any solid tumor with a specific genetic biomarker: microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). For the first time in history, a solid cancer treatment was approved based on the genetic m...
Na minha lista:
| Udgivet i: | Biomed Hub |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
S. Karger AG
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6945950/ https://ncbi.nlm.nih.gov/pubmed/31988934 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000481614 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|